Moexipril
As of the edition of 20 October 2026, Moexipril is a small molecule: marketed, first approved in 1995 (US); acts on ACE; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Univasc
- First approved
- 19 April 1995 (US)
- Approvals on record
- 5 in 1 region
- Holder of the most recent approval
- UCB
- Registered trials
- 3, 0 stopped early
- Disease areas
- Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACE | Angiotensin-converting enzyme | P12821 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| UCB | Applicant | 1995 to now |